Amanda Bostick
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.4% of the total across 171 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by AstraZeneca at 25.7% of the total. 2025 is the largest year on record at $1,964, more than ten times the $81 reported in 2022. Among family clinicians in DE with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 171 payments — averaging $22.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$981
- Gilead$567
- Novo Nordisk$432
- Lilly USA, LLC$314
- Astellas Pharma US Inc$309
- AbbVie$309
- plus $909 from 16 others
What the payments were for
- Food & beverage$3,72197%
- Education$1013%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 35 | $981 |
| Gilead | 18 | $567 |
| Novo Nordisk | 28 | $432 |
| Lilly USA, LLC | 16 | $314 |
| Astellas Pharma US Inc | 14 | $309 |
| AbbVie | 17 | $309 |
| Pfizer | 11 | $191 |
| Sun Pharmaceutical Industries Inc. | 1 | $142 |
| Abbott | 6 | $129 |
| Exact Sciences | 6 | $114 |
| GSK | 3 | $46 |
| Kowa Pharmaceuticals America, Inc. | 3 | $45 |
| Phathom Pharmaceuticals, Inc. | 4 | $44 |
| Tactile Systems Technology Inc | 1 | $26 |
| Medtronic | 1 | $24 |
| Hologic Sales And Service, LLC | 1 | $24 |
| Bayer | 1 | $24 |
| Xeris Pharmaceuticals, Inc. | 1 | $23 |
| Neurocrine Biosciences, Inc. | 1 | $22 |
| Shield Therapeutics Inc | 1 | $20 |
| Sumitomo Pharma America, Inc. | 1 | $18 |
| Merck | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI$428
- AIRSUPRA$297
- FARXIGA$186
- DRIZALMA SPRINKLE$142
- Yeztugo$125
How this compares
$3,822 in reported general payments places this provider in the 90th percentile of 523 family providers in Delaware.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 42 | $61,613 |
| MounjaroTirzepatide | 30 | $40,823 |
| JanuviaSitagliptin Phosphate | 11 | $18,043 |
| TrulicityDulaglutide | 12 | $14,552 |
| LinzessLinaclotide | 16 | $8,316 |
| FarxigaDapagliflozin Propanediol | 14 | $8,109 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 13 | $5,858 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $3,771 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 44 | $1,763 |
| Atorvastatin Calcium | 165 | $1,693 |
| Omeprazole | 89 | $1,653 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $1,624 |
| Metoprolol Succinate | 76 | $1,253 |
| SynthroidLevothyroxine Sodium | 11 | $1,218 |
| Rosuvastatin Calcium | 91 | $1,016 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $432 | $61,61342 claims |
| Lilly USA, LLCMounjaro, Trulicity | $314 | $55,37542 claims |
| MerckJanuvia | $17 | $18,04311 claims |
| AbbVieLinzess, Synthroid | $309 | $9,53527 claims |
| AstraZenecaFarxiga | $981 | $8,10914 claims |
| GSKAnoro Ellipta | $46 | $5,85813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 523 family providers in Delaware.
Other family in Bear
- Kathleen GustafsonBear$15K
- Brandi GreggeMiddletown$110K
- Tracy EstesWilmington$59K
- Kathy GallagherNewark$53K
- Jodie DelesioNewark$50K
- Abby AllenGeorgetown$43K
- Taylor HodgesLewes$33K
- Jodi KahanWilmington$21K
- Valerie HarrisonBridgeville$15K
- Elizabeth Sharp-AsiyoWilmington$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.